T. Rowe Price Associates
DERM icon

T. Rowe Price Associates’s Journey Medical DERM Stock Holding History

T. Rowe Price Associates’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53K Buy
+11,215
New +$87.1K ﹤0.01% 3072

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's DERM Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in Journey Medical (DERM) in Q1 2026: 11,215 shares worth $53K. The stake represents ﹤0.01% of the portfolio and ranks #3072 among its holdings.

71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • T. Rowe Price Associates held 11,215 shares of Journey Medical worth $53K as of Q1 2026.
  • Journey Medical was a new T. Rowe Price Associates position in Q1 2026.
  • Journey Medical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3072 holding.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.